These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38657243)

  • 1. CAR T-Cells and Safety Signals: ITT Episode 29.
    N Engl J Med; 2024 Apr; 390(16):e39. PubMed ID: 38657243
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Frontier: CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Alcocer Alkureishi L; Hageman JR
    Pediatr Ann; 2024 May; 53(5):e157-e158. PubMed ID: 38700917
    [No Abstract]   [Full Text] [Related]  

  • 4. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.
    Melody M; Epperla N; Shouse G; Romancik J; Allen P; Moyo TK; Kenkre V; Ollila T; Fitzgerald L; Hess B; David K; Herr MM; Odetola O; Lin A; Moreira J; Ma S; Winter JN; Roy I; Stephens D; Danilov A; Shah NN; Barta SK; Cortese M; Cohen JB; Gordon LI; Karmali R
    Blood Adv; 2024 May; 8(10):2327-2331. PubMed ID: 38498727
    [No Abstract]   [Full Text] [Related]  

  • 5. T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy.
    Martin LJ; Whitmore JB; Shen RR; Neumann F
    Blood Adv; 2024 Aug; 8(15):4144-4148. PubMed ID: 38861341
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
    Li X; Chen W
    Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
    Hill JA; Seo SK
    Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.
    Haidar G; Garner W; Hill JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):449-457. PubMed ID: 33009139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.
    Sesques P; Bachy E; Ferrant E; Safar V; Gossez M; Morfin-Sherpa F; Venet F; Ader F
    Cancer Cell; 2022 Mar; 40(3):236-237. PubMed ID: 35093212
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
    Quintás-Cardama A
    Leuk Lymphoma; 2019 May; 60(5):1346-1348. PubMed ID: 30646790
    [No Abstract]   [Full Text] [Related]  

  • 14. CAR T cells - what have we learnt?
    Nat Rev Clin Oncol; 2017 Dec; 15(1):1. PubMed ID: 29242589
    [No Abstract]   [Full Text] [Related]  

  • 15. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
    Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B
    Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
    Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
    Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.